No Data
Are Robust Financials Driving The Recent Rally In Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Stock?
Shareholders Shanghai Aixiang and Shanghai Aiyun of Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) are planning to reduce their shareholding by no more than 4.5 million shares through block trade.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company's employee shareholding platform Shanghai Aixiang and Shanghai Aiyun plan to conduct bulk transactions...
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): The controlling shareholder proposes to implement mid-year dividends in 2024.
On July 17th, Gelonhui announced that they received a letter from Mr. Du Jinhao and Ms. Qi Ju, the actual controller of Shanghai Allist Pharmaceuticals Co., Ltd., proposing to implement mid-term dividends for the company in 2024. In order to implement the core idea of "investors first", adhere to the business philosophy of bringing long-term and sustainable returns to investors, and enhance the sense of achievement for investors, based on their confidence in the company's long-term development, Mr. Du Jinhao and Ms. Qi Ju unanimously proposed to develop and implement profit distribution policies that comply with the "Company Law" principles and ensure normal operation and long-term development of the company.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): Received drug clinical trial approval letter for new indication of Venetoclax.
On July 8th, Gelunhui reports that Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued and approved by the National Medical Products Administration. The clinical study of the new indication for sulfonic acid fumeitinib tablets (referred to as "fumeitinib") obtained drug clinical trial approval. Fumeitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which is a type 1 small molecule targeted drug independently developed by the company. Fumeitinib belongs to a highly selective and irreversible third-generation EGFR-TKI, mainly used in the treatment of EGFR mutation non-small cell lung cancer, with the potential to cross the blood-brain barrier.
HKEX Live | WuXi Biologics and Shanghai Allist Pharmaceuticals Co., Ltd. collaborate to conduct clinical research on combination therapy for advanced non-small cell lung cancer, and How Yu-B (02256) surges more than 8% in the afternoon.
Wah Yuet Group B (02256) rose more than 8% in the afternoon. As of press time, it has risen 7.14% to HKD 3.45 with a turnover of HKD 3.1682 million.
With EPS Growth And More, Shanghai Allist Pharmaceuticals (SHSE:688578) Makes An Interesting Case
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Shareholders Might Be Looking For ExitNo Data
